Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5608
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial ; volume:25 ; number:2 ; day:7 ; month:10 ; year:2021 ; pages:363-365 ; date:6.2022
Prostate cancer and prostatic diseases ; 25, Heft 2 (7.10.2021), 363-365, 6.2022
- Urheber
-
Penson, David F.
Armstrong, Andrew J.
Concepcion, Raoul S.
Agarwal, Neeraj
Olsson, Carl A.
Karsh, Lawrence I.
Dunshee, Curtis J.
Duggan, William
Shen, Qi
Sugg, Jennifer
Haas, Gabriel P.
Higano, Celestia S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41391-021-00465-7
- URN
-
urn:nbn:de:101:1-2022082321085933773080
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Penson, David F.
- Armstrong, Andrew J.
- Concepcion, Raoul S.
- Agarwal, Neeraj
- Olsson, Carl A.
- Karsh, Lawrence I.
- Dunshee, Curtis J.
- Duggan, William
- Shen, Qi
- Sugg, Jennifer
- Haas, Gabriel P.
- Higano, Celestia S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States